MoonLake Immunotherapeutics MLTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$69.71M-10.6% | -$63.02M+10.9% | -$70.69M-26.1% | -$56.05M-38.2% | -$40.56M+12.6% | ||
| $845K+12.5% | $751K+0.8% | $745K+0.4% | $742K+96.3% | $378K+3.8% | ||
| $13.36M+272% | $3.59M-3.2% | $3.71M+12.1% | $3.31M+44.5% | $2.29M+18.4% | ||
| -$6.17M-245% | $4.27M-47.9% | $8.2M+61.7% | $5.07M+68.4% | $3.01M— | ||
| $7.12M— | —— | $12.86M+809% | -$1.81M-16.5% | -$1.56M-137% | ||
| $749K— | —— | —— | —— | $1.7M— | ||
| -$422K-559% | $92K— | —— | $1.34M+1,177% | -$124K-126% | ||
| $10.1M+362% | -$3.86M-1,308% | -$274K-107% | $3.84M+1,508% | -$273K-105% | ||
| $11K+135% | -$31K-72.2% | -$18K-260% | -$5K-25.0% | -$4K-200% | ||
| -$389K-3.2% | -$377K+6.0% | -$401K-112% | -$189K+25.9% | -$255K+53.7% | ||
| $894K+5.5% | $847K+38.4% | $612K+45.7% | $420K+188% | $146K-66.5% | ||
| -$66.29M-12.7% | -$58.79M-32.0% | -$44.54M+18.3% | -$54.53M-43.0% | -$38.14M+21.3% | ||
| $0— | —— | —— | —— | $35K-80.1% | ||
| $59.07M-0.2% | $59.17M— | $0-100% | $117.66M+32.9% | $88.55M-39.7% | ||
| $59.17M+102% | $29.26M-66.9% | $88.4M-57.1% | $205.91M+42.2% | $144.83M— | ||
| $98K— | —— | $88.4M+0.2% | $88.25M+56.9% | $56.25M+138% | ||
| $24.47M— | —— | —— | —— | $73.02M— | ||
| $6.01M— | —— | $0— | $0— | $0— | ||
| $30.64M-57.7% | $72.4M+14,982% | $480K— | $0-100% | $73.12M+48,325% | ||
| -$483K-631% | $91K— | —— | $1.39M+1,681% | -$88K-121% | ||
| -$36.03M— | —— | $44.06M+25.5% | $35.12M-61.5% | $91.14M+147% | ||
| $1.82M-16.9% | $2.19M+27.6% | $1.72M+48.4% | $1.16M— | $0— | ||
| $7.12M— | —— | $12.86M+809% | -$1.81M-16.5% | -$1.56M-137% | ||
| -$389K-3.2% | -$377K+6.0% | -$401K-112% | -$189K+25.9% | -$255K+53.7% | ||
| $30K— | $0— | $0— | $0— | $0-100% | ||
| $894K+5.5% | $847K+38.4% | $612K+45.7% | $420K+188% | $146K-66.5% | ||
| $10.1M+362% | -$3.86M-1,308% | -$274K-107% | $3.84M+1,508% | -$273K-105% | ||
| -$422K-559% | $92K— | —— | $1.34M+1,177% | -$124K-126% | ||
| $11K+135% | -$31K-72.2% | -$18K-260% | -$5K-25.0% | -$4K-200% | ||
| $59.17M+102% | $29.26M-66.9% | $88.4M-57.1% | $205.91M+42.2% | $144.83M— | ||
| -$483K-631% | $91K— | —— | $1.39M+1,681% | -$88K-121% | ||
| -$389K-3.2% | -$377K+6.0% | -$401K-112% | -$189K+25.9% | -$255K+53.7% | ||
| $567K— | $0— | $0— | $0— | $0— | ||
| -$66.29M-12.7% | -$58.79M-32.0% | -$44.54M+18.3% | -$54.53M-42.8% | -$38.18M+21.5% | ||
| -$66.29M-12.7% | -$58.79M-32.0% | -$44.54M+18.3% | -$54.53M-42.8% | -$38.18M+21.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does MoonLake Immunotherapeutics generate?
- MoonLake Immunotherapeutics (MLTX) generated -$224.2M in operating cash flow over the trailing twelve months.
- What is MoonLake Immunotherapeutics's free cash flow?
- After $343.0K of capital expenditures, MoonLake Immunotherapeutics's free cash flow was -$224.2M over the trailing twelve months, down 60.0% year over year.
- Where does MoonLake Immunotherapeutics's cash flow data come from?
- Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.